Is UiPath an Undervalued AI Stock to Buy? | PATH Discounted Cash Flow Valuation

[@sameerforyou01]

These videos are highly highly valuable. I have been watching a lot of videos and I am able to understand, business model, business segments, how stock price moves through earning, how companies business model evolve over time. Thank you so much for sharing this knowledge sir.

[@mojtabaasadirad9430]

Hi Parkev, Thanks for sharing this! Some investors challenging UIPATH RPA as a standalone business. Looks like MSFT, CRM and others added RPA as an add-in to their products. So, they become competitors! My thoughts are that smaller businesses and startups that cannot use expensive subscriptions from hyperscalers can leverage UIPATH services. Continued innovation from UIPATH is critical. Would like to get your perspectives on this. Valuations all good.

[@renusastri2802]

It was a good revision of concepts and formulas to derive the intrinsic value. Thanks parkev!

[@davidz7858]

I monitor this stock last months, and feel under $13 is worth to buy. Got 1000 shares for $12.68 yesterday

[@kamskam908]

Very good company today from 14 to 13 only ❤❤ rest companies from 21 to 19 ;)

[@Badjuju22]

Great insight!

[@JaiMataDi-j3d]

Can u compare between SYM and PATH? Which is a better buy?

[@jonf.3918]

I wish you could do a comparison between Uipath stock and Sofi. Please consider it if you see this comment, and thanks for your outstanding videos!

[@pitmaler4439]

Perhaps you can do a video about Nu Holdings. It went down so much, it is very compleling, isn't it?

[@TommyB-l3e]

I agree

[@westcoasteventsandmarketin147]

Hey Parkev, what are your top 5 stocks to buy in 2025 and which is your favorite. I know 2024 your fav is google

[@parkevtatevosiancfa9544]

I am working on those lists and rankings for 2025. You will likely see them later this month or very early next month.

[@ashishmaharaj5483]

Thanks for the insightful video. Any thoughts on Humacyte? Today granted FDA Approval of SYMVES (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma. Only one in the world. Patented. Ripe for a valuation reset?

[@eddierosario1537]

Why in the world is this stock down wtf?

[@nazruluxd]

❤

[@hamiyou]

I guess UIpath needs to attach themselves with Google Ai chip and fluff some news and announcements. They r not attracting investors. In this time when nearly all stock are overvalued UIpatg is undervalued